

10. Komlosi P, Fuson AL, Fintha A, Peti-Peterdi J, Rosivall L, Warnock DG, Bell PD: Angiotensin I conversion to angiotensin II stimulates cortical collecting duct sodium transport. *Hypertension* 42: 195–199, 2003
11. Navar LG, Imig JD, Zou L, Wang C-T: Intrarenal production of angiotensin II. *Semin Nephrol* 17: 412–422, 1997
12. Zhou Y, Boron WF: Role of endogenously secreted angiotensin II in the CO<sub>2</sub>-induced stimulation of HCO<sub>3</sub> reabsorption by renal proximal tubules. *Am J Physiol Renal Physiol* 294: F245–F252, 2008
13. Darby IA, Congiu M, Fernley RT, Sernia C, Coghlan JP: Cellular and ultrastructural location of angiotensinogen in rat and sheep kidney. *Kidney Int* 46: 1557–1560, 1994
14. Terada Y, Tomita K, Nonoguchi H, Marumo F: PCR localization of angiotensin II receptor and angiotensinogen mRNAs in rat kidney. *Kidney Int* 43: 1251–1259, 1993
15. Ingelfinger JR, Zuo WM, Fon EA, Ellison KE, Dzau VJ: In situ hybridization evidence for angiotensinogen messenger RNA in the rat proximal tubule. An hypothesis for the intrarenal renin angiotensin system. *J Clin Invest* 85: 417–423, 1990
16. Satou R, Gonzalez-Villalobos RA, Miyata K, Ohashi N, Urushihara M, Acres OW, Navar LG, Kobori H: IL-6 augments angiotensinogen in primary cultured renal proximal tubular cells. *Mol Cell Endocrinol* 311: 24–31, 2009
17. Pohl M, Kaminski H, Castrop H, Bader M, Himmerkus N, Bleich M, Bachmann S, Theilig F: Intrarenal renin angiotensin system revisited: Role of megalin-dependent endocytosis along the proximal nephron. *J Biol Chem* 285: 41935–41946, 2010
18. Gonzalez-Villalobos R, Klassen RB, Allen PL, Navar LG, Hammond TG: Megalin binds and internalizes angiotensin II. *Am J Physiol Renal Physiol* 288: F420–F427, 2005
19. Pan N, Luo J, Kaiser SJ, Frome WL, Dart RA, Tewksbury DA: Specific receptor for angiotensinogen on human renal cells. *Clin Chim Acta* 373: 32–36, 2006
20. Matsusaka T, Niimura F, Shimizu A, Pastan I, Saito A, Kobori H, Nishiyama A, Ichikawa I: Liver angiotensinogen is the primary source of renal angiotensin II. *J Am Soc Nephrol* 23: 1181–1189, 2012
21. Kobori H, Prieto-Carrasquero MC, Ozawa Y, Navar LG: AT1 receptor mediated augmentation of intrarenal angiotensinogen in angiotensin II-dependent hypertension. *Hypertension* 43: 1126–1132, 2004
22. Kobori H, Harrison-Bernard LM, Navar LG: Expression of angiotensinogen mRNA and protein in angiotensin II-dependent hypertension. *J Am Soc Nephrol* 12: 431–439, 2001
23. Gonzalez-Villalobos RA, Seth DM, Satou R, Horton H, Ohashi N, Miyata K, Katsurada A, Tran DV, Kobori H, Navar LG: Intrarenal angiotensin II and angiotensinogen augmentation in chronic angiotensin II-infused mice. *Am J Physiol Renal Physiol* 295: F772–F779, 2008
24. Navar LG, Kobori H, Prieto MC, Gonzalez-Villalobos RA: Intratubular renin-angiotensin system in hypertension. *Hypertension* 57: 355–362, 2011
25. Christensen EI, Verroust PJ, Nielsen R: Receptor-mediated endocytosis in renal proximal tubule. *Pflügers Arch* 458: 1039–1048, 2009
26. Biemesderfer D: Regulated intramembrane proteolysis of megalin: Linking urinary protein and gene regulation in proximal tubule? *Kidney Int* 69: 1717–1721, 2006
27. Christ A, Terryn S, Schmidt V, Christensen EI, Huska MR, Andrade-Navarro MA, Hübner N, Devuyst O, Hammes A, Willnow TE: The soluble intracellular domain of megalin does not affect renal proximal tubular function in vivo. *Kidney Int* 78: 473–477, 2010
28. Kobori H, Nangaku M, Navar LG, Nishiyama A: The intrarenal renin-angiotensin system: From physiology to the pathobiology of hypertension and kidney disease. *Pharmacol Rev* 59: 251–287, 2007
29. Gonzalez-Villalobos RA, Satou R, Ohashi N, Semprun-Prieto LC, Katsurada A, Kim C, Upchurch GM, Prieto MC, Kobori H, Navar LG: Intrarenal mouse renin-angiotensin system during ANG II-induced hypertension and ACE inhibition. *Am J Physiol Renal Physiol* 298: F150–F157, 2010
30. Lara LS, McCormack M, Semprun-Prieto LC, Shenouda S, Majid DS, Kobori H, Navar LG, Prieto MC: AT1 receptor-mediated augmentation of angiotensinogen, oxidative stress, and inflammation in ANG II-salt hypertension. *Am J Physiol Renal Physiol* 302: F85–F94, 2012
31. Ying J, Stuart D, Hillas E, Gociman BR, Ramkumar N, Lalouel JM, Kohan DE: Overexpression of mouse angiotensinogen in renal proximal tubule causes salt-sensitive hypertension in mice. *Am J Hypertens* 25: 684–689, 2012
32. Tojo A, Onozato ML, Kurihara H, Sakai T, Goto A, Fujita T: Angiotensin II blockade restores albumin reabsorption in the proximal tubules of diabetic rats. *Hypertens Res* 26: 413–419, 2003
33. Kobori H, Nishiyama A, Harrison-Bernard LM, Navar LG: Urinary angiotensinogen as an indicator of intrarenal angiotensin status in hypertension. *Hypertension* 41: 42–49, 2003
34. Satou R, Miyata K, Gonzalez-Villalobos RA, Ingelfinger JR, Navar LG, Kobori H: Interferon- $\gamma$  biphasically regulates angiotensinogen expression via a JAK-STAT pathway and suppressor of cytokine signaling 1 (SOCS1) in renal proximal tubular cells. *FASEB J* 26: 1821–1830, 2012
35. Navar LG, Prieto MC, Satou R, Kobori H: Intrarenal angiotensin II and its contribution to the genesis of chronic hypertension. *Curr Opin Pharmacol* 11: 180–186, 2011

See related article, "Liver Angiotensinogen Is the Primary Source of Renal Angiotensin II," on pages 1181–1189.

## Renal Nerves and CKD: Is Renal Denervation the Answer?

Michael H. Humphreys

Division of Nephrology, San Francisco General Hospital, San Francisco, California; and Department of Medicine, University of California, San Francisco, California

*J Am Soc Nephrol* 23: 1132–1135, 2012.  
doi: 10.1681/ASN.2012050513

A role for renal nerves in the regulation of renal function has been recognized since the time of Claude Bernard.<sup>1</sup> It has also been clear that renal nerves have an intimate relationship with many forms of experimental hypertension,<sup>2</sup> and surgical splancnicectomy, with consequent renal denervation, was a recommended form of therapy for hypertension in humans before the introduction of effective pharmacologic agents,<sup>3</sup> despite the occurrence of serious side effects including orthostatic hypotension, erectile dysfunction, and gastrointestinal symptoms. Interest in renal denervation as an approach to the management of resistant hypertension in humans has recently been renewed with the introduction of an endovascular device, which uses the energy of a radiofrequency signal to ablate adjacent nerves in the vascular wall. When applied in a systematic manner in the lumens of the renal arteries, this approach results in sustained reduction in BP in patients with resistant hypertension.<sup>4</sup>

Published online ahead of print. Publication date available at www.jasn.org.

**Correspondence:** Dr. Michael H. Humphreys, Box 1341, University of California, San Francisco, CA 94143. Email: mhumphreys@medsfgh.ucsf.edu

Copyright © 2012 by the American Society of Nephrology

Given the recognized role of efferent renal nerves in the regulation of renin secretion, tubular sodium reabsorption, and renal hemodynamics, the salutary effect of the radiofrequency ablation procedure on BP could readily be attributed to interruption of efferent sympathetic nerve impulses, resulting in a lowered rate of renin secretion, natriuresis, and improved renal hemodynamics. Surgical renal denervation also delays or prevents many forms of experimental hypertension, although interruption of efferent impulses is not always the basis for this antihypertensive action. The kidneys also have afferent nerve fibers that carry information from mechanoreceptors and chemoreceptors to the central nervous system. Activation of these afferents can increase central sympathetic outflow and cause elevations in BP. Selective deafferentation by cutting the dorsal roots from T9 to L1, called dorsal rhizotomy, interrupts signals from afferent nerves as they enter the spinal column, but leaves efferent pathways intact. This approach can be applied in experimental models of hypertension and has been used to demonstrate important roles of renal afferent nerves in preventing hypertension during ingestion of a high sodium diet<sup>5</sup> or after 5/6 nephrectomy.<sup>6</sup> It is obviously not useful in pursuing the roles of efferent *versus* afferent renal nerve activity in humans, because radiofrequency energy applied to the renal arteries will ablate afferent and efferent nerves.

Hypertension is an almost universal complication of CKD. In this setting, it has usually been thought to result from the interaction of impaired sodium excretion by diseased kidneys coupled with activation of the renin-angiotensin system. However, abundant evidence shows that CKD is a state of sympathetic nervous activation that contributes to hypertension, as well as participates in the progressive loss of renal function.<sup>7,8</sup> This sympathetic hyperactivity persists in patients with ESRD and was initially thought to be a consequence of uremia. However, it persists after renal transplantation when renal function has been normalized but is corrected when the native, diseased kidneys are removed,<sup>9</sup> indicating that the kidneys themselves are responsible for the hyperadrenergic state.<sup>9,10</sup>

Campese and colleagues<sup>11,12</sup> developed an interesting model of experimental hypertension in the rat, which clearly supports a major role for renal afferent nerves: the authors injected a small amount of phenol into the lower pole of one kidney and observed the prompt and long-lasting development of systemic hypertension accompanied by evidence of increased renal sympathetic nerve activity without any overall decrease in renal function. The hypertension and evidence of sympathetic activation did not occur in rats that had undergone dorsal rhizotomy, indicating that afferent traffic from the injected kidney led to the observed changes in CNS norepinephrine metabolism and increased sympathetic outflow.<sup>12</sup> This model provides definitive evidence that even small, functionally insignificant, renal lesions produce hypertension through renal afferent pathways.

The beneficial effects of the radiofrequency ablation procedure on BP in patients with resistant hypertension but with

normal or near-normal renal function<sup>4</sup> led naturally to a consideration of its possible efficacy in patients with hypertension in the setting of CKD. As reported in this issue of *JASN*, Hering *et al.*<sup>13</sup> carried out a two-center pilot study of radiofrequency-mediated renal nerve ablation in 15 patients with moderate to severe CKD (creatinine-based estimated GFR [eGFR]  $31 \pm 9$  [SD] mL/min per  $1.73 \text{ m}^2$ ). Eleven of the 15 had type 2 diabetes, and all had resistant hypertension (average baseline office BP was  $174 \pm 22/91 \pm 16$  mmHg on treatment); their mean age was  $61 \pm 9$  years, and body mass index averaged  $33 \pm 8 \text{ kg/m}^2$ . Eight patients were followed for 6 months and five patients for 12 months. Importantly, there was no evidence of a decline in eGFR or effective renal plasma flow 6 months after the procedure, despite exposure to contrast material in some of the patients; the investigators did not analyze statistically the values at 12 months because of the small number of patients. Office systolic and diastolic BPs were significantly reduced at 3- and 6-month follow-up, although ambulatory BP monitoring over 24 hours did not reveal significant reductions. There was, however, a significant reduction in nighttime BP and in the night-to-day BP ratio, indicating an improvement in so-called dipping toward a more normal value. The authors also noted trends for improvement in hemoglobin A<sub>1C</sub> and plasma brain natriuretic peptide concentrations, an increase in hemoglobin level, and decreases in urinary albumin-to-creatinine ratio, proteinuria, and the augmentation index (a measure of arterial stiffness), although none of these changes reached statistical significance. This pilot study in a small number of CKD patients thus suggests that radiofrequency renal denervation is safe, does not lead to appreciable deterioration of eGFR, and may have beneficial effects on resistant BP and cardiovascular risk factors in such patients.

Before accepting these conclusions, several issues need to be considered. First, were the kidneys successfully denervated by the procedure? Measurement of organ innervation in intact humans can best be done using the technique of norepinephrine spillover pioneered by Esler *et al.*<sup>14</sup> This is an isotope dilution method that determines the contribution of norepinephrine added to the circulation by individual organs and can be used as a marker of sympathetic efferent nerve activity to that organ. It has been successfully applied to the kidneys of hypertensive humans: in a proof-of-principle trial, radiofrequency renal nerve ablation in 10 hypertensive patients with normal renal function reduced renal norepinephrine spillover an average of 47% at 15–30 days after the procedure.<sup>15</sup> The gold standard of effective renal denervation when performed surgically in experimental animals is a reduction of renal norepinephrine content of >90%, so by that standard, catheter ablation may result in only partial efferent denervation. It will certainly be important to determine in future studies the effectiveness of the radiofrequency catheter denervation procedure on norepinephrine spillover in patients with CKD such as those studied in the current report.

A second issue is the possibility of reinnervation of the kidneys. Efferent renal innervation after surgical denervation

can be demonstrated to be complete after 3–4 months in both rats<sup>16</sup> and dogs.<sup>17</sup> Data in humans are sparse. Histologic study of transplanted kidneys showed axonal regeneration as early as 28 days after transplantation, which appeared complete by 8–12 months.<sup>18</sup> However, there was no assessment of the functional significance of these nerves, which were found primarily around the renal vasculature. Another study examined the renal hemodynamic response of transplant recipients *versus* normal controls to lower body negative pressure (LBNP), which reduced mean arterial pressure by 27 mmHg. The authors concluded that the transplanted kidneys remained denervated because the decline in renal blood flow was less than in the control subjects.<sup>19</sup> However, when renal vascular resistance (renal blood flow/arterial pressure) was calculated to factor in the fall in BP resulting from the LBNP, there was no difference between control and transplanted kidneys, suggesting at least partial reinnervation of the latter.<sup>19</sup> These limited data focused primarily on efferent sympathetic renal innervation. Data exploring the question of afferent renal nerve reinnervation after denervation or transplantation are virtually absent. One study in dogs measured the arterial pressure response to capsaicin injected into the renal artery after autotransplantation; in innervated kidneys, this injection raises BP through activation of renal afferent nerve pathways. Twelve to 35 months after autotransplantation, capsaicin produced an increase in BP of 10 mmHg, but this response was only one-third that seen in dogs with native innervated kidneys.<sup>20</sup> This suggests at least partial afferent renal innervation may have taken place after 1 year. These observations do not allow a clear conclusion about the reinnervation of human kidneys after renal denervation. However, the prolonged reduction in BP following catheter-based renal denervation argues that, even if reinnervation takes place, the benefits of the procedure persist for at least 1 year and are not overcome by compensations in other BP regulatory pathways, both in patients with resistant hypertension and near-normal renal function<sup>4,15</sup> and in patients with CKD and severe hypertension.<sup>13</sup>

It must of course be remembered that this is a small study with relatively short-term follow-up, and ultimate safety and efficacy of the catheter-based renal denervation procedure must await longer follow-up in a larger group of patients with CKD; indeed, of the five patients followed for 12 months, eGFR appears to have declined precipitously in one and more gradually in three others compared with the value at 6 months.<sup>13</sup> A trial in a larger group of patients is now underway prior to seeking approval from the Food and Drug Administration for approval of the radiocatheter device. Additionally, the preponderance of patients with type 2 diabetes (11/15) in this pilot study raises the question of benefit in patients with CKD from other causes or with a body mass index that is not so elevated. Not yet answered is the effect of the catheter-based renal denervation on the increased sympathetic tone accompanying CKD; in one case report, whole body norepinephrine spillover, a measure of overall sympathetic activity, was reduced 42% in a patient with resistant

hypertension, although the patient's level of renal function was not presented.<sup>21</sup>

These issues notwithstanding, bilateral renal denervation using this modestly invasive technique appears to offer a new avenue to approach the treatment of resistant hypertension and may have particular utility in reducing the cardiovascular risk profile of patients with CKD. The results of the larger clinical trial now underway are awaited with keen interest.

## ACKNOWLEDGMENTS

The author acknowledges helpful discussions with Gerald F. DiBona, MD.

## DISCLOSURES

None.

## REFERENCES

- Bernard C: *Lecons sur les Proprietes et les Alterations Pathologiques des Liquides de L'Organisme*, Paris, Bailliere et Fils, 1859
- DiBona GF, Kopp UC: Neural control of renal function. *Physiol Rev* 77: 75–197, 1997
- Smithwick RH, Whitelaw GP, Kinsey D: Surgical approach to the treatment of essential hypertension. Results of therapy (medical and surgical). *Am J Cardiol* 9: 893–899, 1962
- Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Böhm M; Symplicity HTN-2 Investigators: Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. *Lancet* 376: 1903–1909, 2010
- Kopp UC, Cicha MZ, Smith LA: Dietary sodium loading increases arterial pressure in afferent renal-denervated rats. *Hypertension* 42: 968–973, 2003
- Campese VM, Kogosov E: Renal afferent denervation prevents hypertension in rats with chronic renal failure. *Hypertension* 25: 878–882, 1995
- Joles JA, Koomans HA: Causes and consequences of increased sympathetic activity in renal disease. *Hypertension* 43: 699–706, 2004
- Schlaich MP, Socratous F, Henneby S, Eikelis N, Lambert EA, Straznicky N, Esler MD, Lambert GW: Sympathetic activation in chronic renal failure. *J Am Soc Nephrol* 20: 933–939, 2009
- Hausberg M, Kosch M, Harmelink P, Barenbrock M, Hohage H, Kisters K, Dietl KH, Rahn KH: Sympathetic nerve activity in end-stage renal disease. *Circulation* 106: 1974–1979, 2002
- Converse RL Jr, Jacobsen TN, Toto RD, Jost CM, Cosentino F, Fouad-Tarazi F, Victor RG: Sympathetic overactivity in patients with chronic renal failure. *N Engl J Med* 327: 1912–1918, 1992
- Ye S, Gamburd M, Mozayeni P, Koss M, Campese VM: A limited renal injury may cause a permanent form of neurogenic hypertension. *Am J Hypertens* 11: 723–728, 1998
- Ye S, Ozgur B, Campese VM: Renal afferent impulses, the posterior hypothalamus, and hypertension in rats with chronic renal failure. *Kidney Int* 51: 722–727, 1997
- Hering D, Mahfoud F, Walton AS, Krum H, Lambert GW, Lambert EA, Sobotka PA, Böhm M, Cremers B, Esler MD, Schlaich MP: Renal denervation in moderate to severe CKD. *J Am Soc Nephrol* 23: 1250–1257, 2012
- Esler M, Jennings G, Lambert G, Meredith I, Horne M, Eisenhofer G: Overflow of catecholamine neurotransmitters to the circulation: source, fate, and functions. *Physiol Rev* 70: 963–985, 1990

15. Krum H, Schlaich M, Whitbourn R, Sobotka PA, Sadowski J, Bartus K, Kapelak B, Walton A, Sievert H, Thambar S, Abraham WT, Esler M: Catheter-based renal sympathetic denervation for resistant hypertension: A multicentre safety and proof-of-principle cohort study. *Lancet* 373: 1275–1281, 2009
16. Kline RL, Mercer PF: Functional reinnervation and development of supersensitivity to NE after renal denervation in rats. *Am J Physiol* 238: R353–R358, 1980
17. Mogil RA, Itskovitz HD, Russell JH, Murphy JJ: Renal innervation and renin activity in salt metabolism and hypertension. *Am J Physiol* 216: 693–697, 1969
18. Gazdar AF, Dammin GJ: Neural degeneration and regeneration in human renal transplants. *N Engl J Med* 283: 222–224, 1970
19. Hansen JM, Abildgaard U, Fogh-Andersen N, Kanstrup IL, Bratholm P, Plum I, Strandgaard S: The transplanted human kidney does not achieve functional reinnervation. *Clin Sci (Lond)* 87: 13–20, 1994
20. Sankari B, Stowe N, Gavin JP, Satoh S, Nally JV, Novick AC: Studies on the afferent and efferent renal nerves following autotransplantation of the canine kidney. *J Urol* 148: 206–210, 1992
21. Schlaich MP, Sobotka PA, Krum H, Lambert E, Esler MD: Renal sympathetic-nerve ablation for uncontrolled hypertension. *N Engl J Med* 361: 932–934, 2009

---

See related article, “Renal Denervation in Moderate to Severe CKD,” on pages 1250–1257.